GuidelineHPB : the official journal of the International Hepato Pancreato Biliary Association2013
Selection for hepatic resection of colorectal liver metastases: expert consensus statement.
Guideline in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 8 syntheses or guidelines pooled it, 343 citations in OpenAlex.
- Missing colorectal liver metastases: the surgical challenge.Langenbeck's archives of surgery · 2021Pooled it
- Open Resection Compared to Mini-Invasive in Colorectal Cancer and Liver Metastases: A Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Mini-invasiveWorld journal of gastroenterology · 2019Pooled it
- Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2016Pooled it
- ALPPS Procedure for Extended Liver Resections: A Single Centre Experience and a Systematic Review.PloS one · 2015Pooled it
- A systematic review of repeat hepatectomy for recurrent colorectal liver metastases.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2013Pooled it
- Selection for hepatic resection: expert consensus conference.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2013Guideline
- BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgeryGuideline
- Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up.Radiation oncology (London, England) · 2018Trial
- A Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-controlled Analgesia After Major Hepatopancreatobiliary Surgery.Annals of surgery · 2017Trial
- The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases.BMC medical imaging · 2014Trial
- Article
- Review
- Article
- Review
- Exploring radiomics as a predictor of hypertrophy of future liver remnant after portal vein embolization in biliary malignancies: a retrospective cohort study.Abdominal radiology (New York) · 2026Article
- Treatment of oligometastatic disease in colorectal cancer: from molecular biology to multimodal strategies.Oncology reviews · 2026Review
- Free-breathing phase-sensitive inversion recovery TMagnetic resonance in medicine · 2026Article
- Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver.PloS one · 2026Article
- Clinicopathological insights and management of liver metastases: Current advances and future perspectives.World journal of hepatology · 2025Review
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic resection offers a chance of a cure in selected patients with colorectal liver metastases (CLM). To achieve adequate patient selection and curative surgery, (i) precise assessment of the extent of disease, (ii) sensitive criteria for chemotherapy effect, (iii) adequate decision making in surgical indication and (iv) an optimal surgical approach for pre-treated tumours are required. For assessment of the extent of the disease, contrast-enhanced computed tomography (CT) and/or magnetic resonance imaging (MRI) with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is recommended depending on the local expertise and availability. Positron emission tomography (PET) and PET/CT may offer additive information in detecting extrahepatic disease. The RECIST criteria are a reasonable method to evaluate the effect of chemotherapy. However, they are imperfect in predicting a pathological response in the era of modern systemic therapy with biological agents. The assessment of radiographical morphological changes is a better surrogate of the pathological response and survival especially in the patients treated with bevacizumab. Resectability of CLM is dependent on both anatomic and oncological factors. To decrease the surgical risk, a sufficient volume of liver remnant with adequate blood perfusion and biliary drainage is required according to the degree of histopathological injury of the underlying liver. Portal vein embolization is sometimes required to decrease the surgical risk in a patient with small future liver remnant volume. As a complete radiological response does not signify a complete pathological response, liver resection should include all the site of a tumour detected prior to systemic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.